Project Grant R01AG103150
- The National Institute on Aging awarded the University of Pennsylvania $811,172 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a five-year prospective observational study testing whether economic scarcity affects medication adherence and uptake of preventive services among older adults with chronic disease. The research enrolls 400 adults aged 50 years or older who receive Supplemental Nutrition Assistance Program (SNAP) benefits and are prescribed once-daily...
- The National Institute on Aging awarded the University of Pittsburgh $619,577 on September 1, 2026, under the Aging Research program (CFDA 93.866) for statistical methods development in spatial proteogenomics data analysis applied to Alzheimer's disease research. The project develops computational and statistical methods to advance spatial proteogenomics analysis, which integrates spatially resolved protein and transcript information to examine cellular organization in brain tissue. In Aim 1,...
- The National Institute on Aging awarded The Rand Corporation $1.366 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to conduct analyses of Medicare beneficiary access to medications for opioid use disorder and assess the impacts of state and federal policies on treatment disparities and health outcomes. The research examines barriers to access for the three FDA-approved medications to treat opioid use disorder: methadone, buprenorphine, and naltrexone. The study...
- The National Institute on Aging awarded the University of Pennsylvania $2,414,176 on September 1, 2026, under the Aging Research program (CFDA 93.866) to examine Medicaid coverage transitions and instability among older adults and evaluate policy interventions that mitigate disruption-related impacts on care and health outcomes. The project will analyze three distinct coverage disruption scenarios using national surveys and linked Centers for Medicare & Medicaid Services data. Aim 1 examines...
- Federal Grant Award Summary The University of Pittsburgh received a $3.1 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective September 1, 2025, through August 31, 2029. This award supports biomedical research investigating the mechanistic relationship between persistent DNA damage-induced immune responses and aging. Specifically, the research examines how the cGAS-STING (cyclic GMP-AMP synthase–stimulator of interferon genes)...
- The National Institute on Aging awarded the University of Pennsylvania $825,128 on September 1, 2026, under the Aging Research program (CFDA 93.866) to identify drivers of variation in home health outcomes and clarify how differences in care processes contribute to disparities in patient outcomes across demographic groups. The project will develop group-specific process and outcome measures to assess variations in care by patient grouping, addressing gaps in current Medicare quality metrics that...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $701,569 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the use and effectiveness of medications for opioid use disorder in older adults with multimorbidity. The award funds quantitative studies of Medicare and Veterans Health Administration enrollees with diagnosed opioid use disorder and a qualitative study of older adults with opioid use disorder and...
- The National Institute on Aging awarded the University of Pittsburgh $664,619 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop multiscale computational and experimental models of neurometabolic coupling across age-related cognitive decline and late-onset Alzheimer's disease. The research integrates in vivo two-photon microscopy, multispectral wide-field imaging, and magnetic resonance imaging to characterize the relationship between neuronal activity and metabolic...
- The National Institute on Aging awarded the University of Pittsburgh $673,702 on September 1, 2026, under the Aging Research program (CFDA 93.866) to support research deciphering ubiquilin-mediated proteostasis mechanisms in Alzheimer's disease and related dementias. The research addresses knowledge gaps in ubiquilin function and protein homeostasis defects underlying neurodegenerative disease. The project will elucidate how STI1 domain binding and E3 ligase recruitment affect cellular fitness...
- The National Institute on Aging awarded the University of Pittsburgh $484,635 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop in vitro aging of cartilage in a microphysiological knee joint system. The recipient will extend the "minijoint," a microphysiological system representing critical joint tissues (cartilage, bone, synovium, adipose) and using microfluidics, to recapitulate the transition of chondrocytes from young and healthy to aged and...
The National Institute on Aging awarded the University of Pittsburgh $654,682 on September 4, 2026, under the Aging Research program (CFDA 93.866) to assess drug shortage intensity, identify factors associated with higher-intensity shortages in pharmaceutical supply chains, and develop an at-risk medicine list prioritizing drugs critical to older adults' care. The research addresses medication access disruptions affecting older adults, who receive most prescriptions dispensed in the U.S. and depend on medications manufactured predominantly overseas. Prior work on drug shortages has focused on presence or absence of shortage events while ignoring variability in shortage duration and supply decrease magnitude. The study will pursue three specific aims: measure and compare shortage intensity and associated factors in the U.S. and Canada; develop a U.S.-specific at-risk medicine list considering clinical importance and supply chain disruptions; and determine the validity, accuracy, and usability of operationalizing an at-risk medicine list. The approach combines innovative dataset integration guided by preliminary data to inform interventions mitigating severe or prolonged medication disruptions. Performance occurs in Pittsburgh, Pennsylvania, with a period extending from award date through June 30, 2031. The award is classified as a Project Grant, an assistance type under NIH's investigator-initiated research mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $654.7k | 9/3/26 |